p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

Table 1

Synergistic response of small molecules with various anticancer agents.

Drug	Synergistic drug	Target	Reference
Nutlin	Melphalan	WT p53, MDM2	[58]
Nutlin	Etoposide	WT p53, MDM2	[58]
Nutlin	Bortezomib	WT p53, MDM2	[60, 61]
Nutlin	Lexatumumab	WT p53, MDM2, DR5	[85]
Nutlin	RITA	WT p53, MDM2	[65]
RITA	MI-63	WT p53, mutant p53	[67]
PRIMA-1	Dexamethasone	p53-independent	[79]
PRIMA-1	Doxorubicin	p53-independent	[79]